Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Anke Görlitz, Peter Dreger, MD, Jörg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1974.

https://doi.org/10.1182/blood.V112.11.1974.1974

Published: 2008

Journal Articles

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Peter Dreger, MD, Martin Gramatzki, MD, Joerg Schubert, MD, Gerald G. Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 3043.

https://doi.org/10.1182/blood.V110.11.3043.3043

Published: 2007

Journal Articles

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Justin Hasenkamp, MD, Imme Conradi, MD, Gerald Wulf, MD, PhD, Wolfram Jung, MD, Lorenz Truemper, MD, PhD, Bertram Glass, MD, PhD

Blood (2004) 104 (11): 1139.

https://doi.org/10.1182/blood.V104.11.1139.1139

Published: 2004

NARROW

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Email alerts

ASH Publications

American Society of Hematology

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only